Smith & Nephew plc (SNN)

Market Cap	12.13B -21.6%
Revenue (ttm)	6.30B +6.0%
Net Income	635.00M +29.3%
EPS	1.47 +31.8%
Shares Out	851.12M
PE Ratio	19.78
Forward PE	12.80
Dividend	$0.76 (2.63%)
Ex-Dividend Date	Oct 2, 2026

Volume	1,938,301
Open	28.71
Previous Close	27.88
Day's Range	28.48 - 29.10
52-Week Range	26.12 - 37.51
Beta	0.67
Analysts	Hold
Price Target	32.32 (+11.1%)
Earnings Date	Aug 4, 2026

About SNN

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 16, 1999
• Employees: 16,988
• Stock Exchange: NYSE
• Ticker Symbol: SNN
• Website: https://www.smith-nephew.com

Financial Performance

In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.

Analyst Summary

According to 6 analysts, the average rating for SNN stock is "Hold." The 12-month stock price target is $32.32, which is an increase of 11.10% from the latest price.

Price Target

$32.32

(11.10% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error